Company / SG&A Expense
TG Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$232.0M
FY2025
5-year range
$95.5M / $232.0M
FY2021-FY2025
Trend
+50.4%
vs FY2024
Sector context
#64 of 213
Health Care
What the data says
At $232M, TG Therapeutics, Inc.'s sg&a expense ranks #150 of 213 in the Health Care sector. SG&A Expense has increased for 3 consecutive years, from $95M in FY2022 to $232M in FY2025.
Based on SEC 10-K filings.
$232M in FY2025 with a 5-year CAGR of +16.6%.
Increased from $123M to $232M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +34.4%
- 5-Year CAGR
- +16.6%
- 10-Year CAGR
- -
Sector benchmark
#150 of 213 in Health CareTop 70% of 213This company $232.0M Sector average $722.3M
▼
-67.9% below sector average
Key checks
Key Insights
- TG Therapeutics, Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +16.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 50.4% year-over-year.
- Ranks #64 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $232.0M | +50.4% |
| FY2024 | $154.3M | +25.7% |
| FY2023 | $122.7M | +28.5% |
| FY2022 | $95.5M | -25.5% |
| FY2021 | $128.1M | +18.8% |
| FY2020 | $107.8M | +560.4% |
| FY2019 | $16.3M | +7.7% |
| FY2018 | $15.2M | -7.2% |
| FY2017 | $16.3M | +65.1% |
| FY2016 | $9.9M | -36.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026